{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:03:14Z","timestamp":1789632194854,"version":"build-2803163510"},"reference-count":32,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15831","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:42Z","timestamp":1787653182000},"page":"1-12","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of ICI\u2011based triple combination therapy for gene\u2011negative advanced lung adenocarcinoma"],"prefix":"10.3892","volume":"32","author":[{"given":"Diwei","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fuling Hospital Affiliated to Chongqing University, Fuling, Chongqing 408000, PR\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Tenth Affiliated Hospital (Dongguan People's Hospital), Southern Medical University, Dongguan, Guangdong 523109, PR.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine, South China University of Technology, Guangzhou, Guangdong 511442, PR.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong 528200, PR. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"key20260917101325_b1-ol-32-4-15831","first-page":"307","article-title":"The global cancer statistics report in 2022: A narrow spectrum summary and outlook","volume":"51","author":"Li","year":"2024","journal-title":"Cancer Res Prev Treat"},{"key":"key20260917101325_b2-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"key20260917101325_b3-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2147\/CMAR.S187317","article-title":"Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades","volume":"11","author":"Lu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"key20260917101325_b4-ol-32-4-15831","article-title":"Diagnosis and treatment of non-small cell lung cancer 2025","author":"Chinese Society of Clinical Oncology","year":"2025"},{"key":"key20260917101325_b5-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.014","article-title":"Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018","volume":"183","author":"Bylicki","year":"2023","journal-title":"Eur J Cancer"},{"key":"key20260917101325_b6-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jamaoncol.2023.5258","article-title":"Atezolizumab and platinum plus pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer: A phase 3 randomized clinical trial","volume":"10","author":"Shiraishi","year":"2024","journal-title":"JAMA Oncol"},{"key":"key20260917101325_b7-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00330-009-1685-y","article-title":"RECIST revised: Implications for the radiologist. A review article on the modified RECIST guideline","volume":"20","author":"Yan Persijn van Meerten","year":"2010","journal-title":"Eur Radiol"},{"key":"key20260917101325_b8-ol-32-4-15831","article-title":"Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. U.S","author":"National Cancer Institute","year":"2017"},{"key":"key20260917101325_b9-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20260917101325_b10-ol-32-4-15831","first-page":"441","article-title":"Proposals for revisions of the TNM descriptors in the eighth edition of the TNM classification for lung cancer","volume":"37","author":"Zhang","year":"2016","journal-title":"World Clinical Drugs"},{"key":"key20260917101325_b11-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"key20260917101325_b12-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"key20260917101325_b13-ol-32-4-15831","first-page":"100620","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"key20260917101325_b14-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: Targeting the tumor microenvironment","volume":"18","author":"Zhao","year":"2022","journal-title":"Int J Biol Sci"},{"key":"key20260917101325_b15-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"175586","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"key20260917101325_b16-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150.423k45_4150_4166","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"key20260917101325_b17-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"key20260917101325_b18-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J"},{"key":"key20260917101325_b19-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260917101325_b20-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jtho.2022.04.001","article-title":"Bevacizumab plus atezolizumab after progression on atezolizumab monotherapy in pretreated patients with NSCLC: An open-label, two-stage, phase 2 trial","volume":"17","author":"Lee","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20260917101325_b21-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"S618","DOI":"10.1016\/j.jtho.2023.09.1171","article-title":"EP11.02\u201309 Rh-endostatin combined with PD-1 inhibitors as first-line treatment for EGFR\/ALK-negative, non-squamous NSCLC","volume":"18","author":"Wang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"key20260917101325_b22-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.21037\/tlcr-23-260","article-title":"Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: A retrospective comparative cohort study","volume":"12","author":"Yu","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"key20260917101325_b23-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jtho.2020.11.026","article-title":"Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC","volume":"16","author":"Chu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20260917101325_b24-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.iotech.2023.100552","article-title":"80P Efficacy and safety of tislelizumab combined with anlotinib and 2-cycle chemotherapy as first-line treatment for advanced NSCLC (TISAL-FE-01)","volume":"20","author":"Tang","year":"2023","journal-title":"Immunooncol Technol"},{"key":"key20260917101325_b25-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2025.05.016","article-title":"64O Lenvatinib plus pembrolizumab, pemetrexed and a platinum as first-line therapy for metastatic nonsquamous (NSCLC): phase 3 LEAP-006 study","volume":"20","author":"Herbst","year":"2025","journal-title":"J Thorac Oncol"},{"key":"key20260917101325_b26-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: A randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260917101325_b27-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.lungcan.2018.08.019","article-title":"Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study","volume":"125","author":"Gadgeel","year":"2018","journal-title":"Lung Cancer"},{"key":"key20260917101325_b28-ol-32-4-15831","first-page":"12401252","article-title":"LncRNA NEAT1 targets miR-379-3p to regulate autophagy in pemetrexed chemotherapy resistance in lung adenocarcinoma","volume":"47","author":"He","year":"2025","journal-title":"Zhejiang Medical Journal"},{"key":"key20260917101325_b29-ol-32-4-15831","first-page":"1011","article-title":"Targeting folate cycle enhances effects of cancer immunotherapy by modulating myeloid-derived suppressor cells","volume":"44","author":"He","year":"2024","journal-title":"Journal of Shanghai Jiao Tong University (Medical Science)"},{"key":"key20260917101325_b30-ol-32-4-15831","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.jtho.2021.05.005","article-title":"Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): A randomized phase 3 trial","volume":"16","author":"Lu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20260917101325_b31-ol-32-4-15831","first-page":"1607","article-title":"Progress of metabolic syndrome in endometrial cancer and its tumor microenvironment","volume":"52","author":"Kong","year":"2023","journal-title":"Shaanxi Medical Journal"},{"key":"key20260917101325_b32-ol-32-4-15831","first-page":"1105","article-title":"Expert consensus on the diagnosis and treatment of coexistent pulmonary tuberculosis and lung cancer","volume":"47","author":"Lu","year":"2025","journal-title":"Chin J Antituberc"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:14:17Z","timestamp":1789629257000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,25]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15831","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}